Clinical trial NCT04115176: GCF IL-17 Levels and Oxidative Status of Smoking and Non-smoking Individuals With Periodontitis
Official title: Smoking Effects on GCF GCF IL-17A AND IL-17 Levels and Oxidative Status of Patients Receiving Periodontal Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Periodontitis
Smoking, Cigarette
Keywords: chronic periodontitis
smoking,
periodontal treatment,
IL-17,
oxidative stress
Lead sponsor: Ondokuz Mayıs University
Sponsor class: OTHER
First posted: 2019-10-03
Enrollment: 30
Sex: ALL
Minimum age (years): 35
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with chronic periodontitis (with an age range of 35 to 60 years) seeking dental treatment at the Periodontology Clinic, School of Dentistry, Ondokuz Mayis University, were included in the present study.

Brief summary: This study was performed to evaluate the effects of both periodontal treatment and smoking on the gingival crevicular fluid(GCF) levels of interleukin (IL)-17A, IL-17E, Total oxidative stress(TOS) and total antioxidant capasity(TAOC) in smoking and non-smoking patients with severe chronic periodontitis.

Systemically healthy 15 smoker,15 non-smoker with chronic periodontitis were attended for the study. Periodontal status were determined by recording periodontal clinical measurements. GCF samples were collected at the baseline, at the end of initial periodontal treatment and 4 weeks after periodontal flap surgery. The data were tested statistically by the Student t and paired sample t tests.


Eligibility criteria: Inclusion Criteria:

* individuals aged ˃35 years and having ≥16 teeth diagnosed as chronic periodontitis
* not received any periodontal therapy within the previous 6 months;
* not received antibiotic/anti-inflammatory drug treatment within the previous 6 months.

Exclusion Criteria:

* receiving medical treatment for cancer, rheumatoid arthritis, diabetes mellitus, cardiovascular disease, or any other systemic disease;
* being pregnant or being in the period of menopause or lactation;
* receiving any drug therapy that might affect the clinical characteristics of periodontitis;
* usage of systemic antimicrobials during the 6 weeks prior to data collection

Primary outcomes:
measure: GCF IL-17A VOLUME
timeFrame: GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .
measure: GCF IL-17E VOLUME
timeFrame: GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .
measure: GCF TOTAL OXIDATIVE STRESS (TOS) LEVEL
timeFrame: GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .
measure: GCF TOTAL ANTIOXIDANT CAPASITY (TAOC)
timeFrame: GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .
Secondary outcomes:
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Müge Lütfioğlu
state: Atakum
Study officials:
affiliation: assoc. prof.
name: MÜGE LÜTFİOĞLU
role: PRINCIPAL_INVESTIGATOR
References: